Jen and Yingzi are in the problem-solving business.
Every day, they tackle one of the toughest health care problems: cancer. While many others like them across the biopharmaceutical industry work tirelessly in pursuit of new treatments and cures in other disease areas for America’s patients.
Jen, Yingzi and their colleagues have contributed complex research that over the course of time has helped decrease America’s cancer death rate 23 percent since its peak in 1991. This is just one example of the tremendous progress made in treating a disease, but it has been no easy feat.
Researching and developing innovative medicines is a challenging undertaking – and the science is only getting harder. As our understanding of science grows, so does the complexity of developing new medicines, particularly as treatments are increasingly become personalized to individual patients. But researchers and scientists persevere in their pursuit of innovative treatments that could help patients live longer, healthier lives. With over 7,000 new medicines currently in development around the world, patients and families across the United States have more hope for a better quality of life.
Jen and Yingzi are just two examples of the men and women who work day in and day out to advance the science of hope. In 2016, PhRMA’s “From Hope to Cures” campaign is highlighting the value biopharmaceutical research is contributing to the development of innovative treatments and cures for patients, society and the economy. In addition to sharing real stories from researchers and patients alike, the effort highlights data and information on fighting disease, clinical trials and the economic contributions from the biopharmaceutical industry.
Highlighting the innovation and promise of medicines in development is critical to fostering the development of tomorrow’s treatments and cures. Explore Patients, Science, Health Care and Economy to better understand the ecosystem of innovation in the biopharmaceutical industry.
Learn more here about the campaign and how America’s biopharmaceutical companies are driving innovation, collaborating and helping to translate new findings into hope for America’s patients.
View the campaign’s multimedia news release here.
Ieva M. Augstums Ieva (YEH-vuh), Deputy Vice President of Public Affairs, joined PhRMA in 2014 and now oversees all branding and paid advertising, including PhRMA’s national multi-year GOBOLDLY campaign. She reported on the 2008 financial crisis and other financial market news during ten years as a journalist at the Dallas Morning News and the Associated Press, then directed national campaigns at a Washington-based strategic communications and brand consulting firm. A native Nebraskan, Ieva is a proud mother of two, dreams of opening a paperie and never passes up an opportunity to lace up for a rave run.